Anthrocell is currently developing a portfolio of biobetters with a focus on oncology applications. It believes that theAnthroCell® platform confers improved efficacy and a reduced side-effect profile on mAbs designed to recruit the effector function of the immune system.

At present, two mAbs have been identified with a promising outlook for oncology patients. Utilising the AnthroCell® platform for their development and production, the company has completed the proof of concept stage and has one candidate in the lead discovery phase.